Cilostazol, a Type III Phosphodiesterase Inhibitor, Reduces Ischemia/Reperfusion-Induced Spinal Cord Injury
DOI:
https://doi.org/10.1532/HSF98.20101126Abstract
Background: Spinal cord injury is still a devastating complication after surgical repair of thoracoabdominal aortic pathologies. In this study, we investigated the protective effect of cilostazol, a type III phosphodiesterase inhibitor, against ischemia/reperfusion (I/R)-induced spinal cord injury in rats.
Methods: Twenty-four rats were assigned to 3 experimental study groups: the control group (sham operation, n = 8); the ischemia group (nontreated, n = 8), which underwent aortic occlusion without pharmacologic intervention; and the cilostazol-treated group (n = 8), which received 20 mg/kg cilostazol per day orally for 3 days before spinal ischemia. All animals underwent a 45-minute period of spinal cord ischemia via clamping of the abdominal aorta between the left renal artery and the aortic bifurcation; removal of the aortic clamp was followed by reperfusion. Neurologic status was assessed before spinal ischemia and at 48 hours after the operation. All animals were sacrificed at 48 hours after the operation. Spinal cords were harvested for histopathologic examination and biochemical analyses for the malondialdehyde (MDA) level and superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities.
Results: Tarlov scores at postoperative hour 48 tended to be higher in the cilostazol-treated group than in the nontreated ischemia group (mean ± SD, 3.66 ± 0.40 versus 2.32 ± 0.80; P = .08). Spinal cord tissue MDA levels (per gram protein) were lower in the cilostazol-treated group than in the nontreated ischemia group (0.27 ± 0.01 mmol/g versus 0.33 ± 0.04 mmol/g, P = .026), and the cilostazol-treated group had higher activities of tissue SOD (519.6 ± 56.3 U/g versus 438.9 ± 67.4 U/g, P = .016) and GSH-Px (4.07 ± 1.37 U/g versus 3.21 ± 1.02 U/g, P = .47) than the nontreated ischemia group. Histopathologic analyses demonstrated that cilostazol treatment attenuated I/R-induced cellular damage.
Conclusion: Administration of cilostazol before spinal cord ischemia reduced neurologic injury and produced clinical improvement by attenuating oxidative stress in this rat spinal cord I/R model.
References
Awad H, Ankeny DP, Guan Z, Wei P, McTigue DM, Popovich PG. 2010. A mouse model of ischemic spinal cord injury with delayed paralysis caused by aortic cross-clamping. Anesthesiology 113:880-91.nBisleri G, Tisi G, Negri A, et al. 2005. The bicircuit system: innovative perfusional options for surgical treatment of the thoracic aorta. Ann Thorac Surg 79:678-80.nBoyle EJ, Pohlman TH, Cornejo CJ, Verrier ED. 1996. Endothelial cell injury in cardiovascular surgery: ischemia-reperfusion. Ann Thorac Surg 62:1868-75.nChoi JM, Shin HK, Kim KY, Lee JH, Hong KW. 2002. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300:787-93.nCoselli JS, LeMaire SA, Koksoy C, Schmittling ZC, Curling PE. 2002. Cerebrospinal fluid drainage reduces paraplegia after thoracoabdominal aortic aneurysm repair: results of a randomized clinical trial. J Vasc Surg 35:631-9.nCoselli JS, LeMaire SA, Poli de Figueiredo L, Kirby RP. 1997. Paraplegia after thoracoabdominal aortic aneurysm repair: Is dissection a risk factor? Ann Thorac Surg 63:28-36.nDickens BF, Mak IT, Weglicki WB. 1988. Lysosomal lipolytic enzymes, lipid peroxidation, and injury. Mol Cell Biochem 82:119-23.nDobashi K, Ghosh B, Orak JK, Singh I, Singh AK. 2000. Kidney ischemia-reperfusion: modulation of antioxidant defenses. Mol Cell Biochem 205:1-11.nGüler A, Sahin MA, Ucak A, et al. 2010. Protective effects of angiotensin II type-1 receptor blockade with olmesartan on spinal cord ischemia-reperfusion injury: an experimental study on rats. Ann Vasc Surg 24:801-8.nHonda F, Imai H, Ishikawa M, et al. 2006. Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. Stroke 37:223-8.nKimura Y, Tani T, Kanbe T, Watanabe K. 1985. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimmittelforschung 35:1144-9.nKirsch JR, Helfaer MA, Lange DG, Traystman RJ. 1992. Evidence for free radical mechanisms of brain injury resulting from ischemia/reperfusion-induced events. J Neurotrauma 9:157-63.nKohda N, Tani T, Nakayama S, et al. 1999. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 96:261-8.nLee JH, Kim YH, Lee YK, et al. 2004. Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphate and tension homolog deleted from chromosome 10 phosphorylation in rats. J Pharmacol Exp Ther 308:896-903.nLee JH, Lee YK, Ishikawa M, et al. 2003. Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats—an MRI study. Brain Res 994:91-8.nLowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-75.nManickavasagam S, Ye Y, Lin Y, et al. 2007. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther 21:321-30.nOhkawa H, Ohishi N, Yagi K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-8.nOta H, Eto M, Kano MR, et al. 2008. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol 28:1634-9.nPaglia DE, Valentine WN. 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158-69.nSekiguchi M, Aoki Y, Konno S, Kikuchi S. 2008. The effects of cilostazol on nerve conduction velocity and blood flow: acute and chronic cauda equina compression in a canine model. Spine (Phila Pa 1976) 33:2605-11.nSun Y, Oberley LW, Li Y. 1988. A simple method for clinical assay of superoxide dismutase. Clin Chem 34:497-500.nTakei K, Tokuyama K, Kato M, Morikawa A. 1998. Role of cyclic adenosine monophosphate in reducing superoxide anion generation in guinea pig alveolar macrophages. Pharmacology 57:1-7.nTanaka K, Gotoh F, Fukuuchi Y, et al. 1989. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 20:668-73.nTarlov IM. 1972. Acute spinal cord compression in paralysis. J Neurosurg 36:10-20.nUeno T, Furukawa K, Katayama Y, Suda H, Itoh T. 1994. Spinal cord protection: development of a paraplegia-preventive solution. Ann Thorac Surg 58:116-20.nWada T, Yao H, Miyamoto T, Mukai S, Yamamura M. 2001. Prevention and detection of spinal cord injury during thoracic and thoracoabdominal aortic repairs. Ann Thorac Surg 72:80-5.nWatanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. 2006. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 37:1539-45.n
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
